These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15690683)

  • 1. Resistance trends in Streptococcus pneumoniae (PROTEKT years 1-3 [1999-2002]).
    Schito GC
    J Chemother; 2004 Dec; 16 Suppl 6():19-33. PubMed ID: 15690683
    [No Abstract]   [Full Text] [Related]  

  • 2. Resistance phenotypes and multi-drug resistance in Streptococcus pneumoniae (PROTEKT years 1-3 [1999-20021).
    Reinert RR
    J Chemother; 2004 Dec; 16 Suppl 6():35-48. PubMed ID: 15690684
    [No Abstract]   [Full Text] [Related]  

  • 3. Resistance trends in Streptococcus pyogenes (PROTEKT years 1-3 [1999-2002]).
    Cohen R; Green M
    J Chemother; 2004 Dec; 16 Suppl 6():71-82. PubMed ID: 15690687
    [No Abstract]   [Full Text] [Related]  

  • 4. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003).
    Schito GC; Felmingham D
    Int J Antimicrob Agents; 2005 Dec; 26(6):479-85. PubMed ID: 16289710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4.
    Jenkins SG; Brown SD; Farrell DJ
    Ann Clin Microbiol Antimicrob; 2008 Jan; 7():1. PubMed ID: 18190701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance trends in Haemophilus influenzae (PROTEKT years 1-3 [1999-20021).
    Low DE
    J Chemother; 2004 Dec; 16 Suppl 6():49-61. PubMed ID: 15690685
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular characterization of the first telithromycin-resistant Streptococcus pneumoniae isolate in Germany.
    Reinert RR; van der Linden M; Al-Lahham A
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3520-2. PubMed ID: 16048973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance trends in Moraxella catarrhalis (PROTEKT years 1-3 [1999-2002]).
    Canton R
    J Chemother; 2004 Dec; 16 Suppl 6():63-70. PubMed ID: 15690686
    [No Abstract]   [Full Text] [Related]  

  • 9. Resistance trends in Staphylococcus aureus (PROTEKT years 1-3 [1999-2002]).
    Jenkins SG
    J Chemother; 2004 Dec; 16 Suppl 6():83-91. PubMed ID: 15690688
    [No Abstract]   [Full Text] [Related]  

  • 10. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004.
    Felmingham D; Cantón R; Jenkins SG
    J Infect; 2007 Aug; 55(2):111-8. PubMed ID: 17568680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction to PROTEkT: years 1-3 (1999-2002).
    Harding I
    J Chemother; 2004 Dec; 16 Suppl 6():5-7. PubMed ID: 15690681
    [No Abstract]   [Full Text] [Related]  

  • 12. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3.
    Jenkins SG; Farrell DJ; Patel M; Lavin BS
    J Infect; 2005 Dec; 51(5):355-63. PubMed ID: 15950288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the Ketolide Telithromycin: results from the PROTEKT surveillance study (1999-2000).
    Reinert RR; Rodloff AC; Halle E; Baer W; Beyreiss B; Seifert H; Wichelhaus TA; Maass M; Mehl M
    Chemotherapy; 2004 Jun; 50(3):143-51. PubMed ID: 15272227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of penicillin resistance in Streptococcus pneumoniae and use of co-trimoxazole in treatment of pneumococcal pneumoniae.
    Lalitha MK; Manoharan A; Pai R; Thomas K
    J Clin Microbiol; 1999 Aug; 37(8):2743-4. PubMed ID: 10447408
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS).
    Wierzbowski AK; Karlowsky JA; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2009 Mar; 63(3):620-2. PubMed ID: 19151038
    [No Abstract]   [Full Text] [Related]  

  • 16. First report on multidrug-resistant non-encapsulated Streptococcus pneumoniae isolated from a patient with pneumonia.
    Takeuchi N; Ohkusu M; Hishiki H; Fujii K; Hotta M; Murata S; Ishiwada N
    J Infect Chemother; 2020 Jul; 26(7):749-751. PubMed ID: 32409019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro effects of penicillin and telithromycin on the expression of Streptococcus pneumoniae capsule.
    Brook I; Hausfeld JN
    J Antimicrob Chemother; 2006 Sep; 58(3):678-9. PubMed ID: 16840431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Activity of different antimicrobial agents against penicillin-resistant Streptococcus pneumoniae].
    Calvo A; Amores R; Valero E; Sevillano D; Prieto J;
    Rev Esp Quimioter; 2001 Dec; 14(4):345-50. PubMed ID: 11856980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacteremic pneumonia caused by extensively drug-resistant Streptococcus pneumoniae.
    Kang CI; Baek JY; Jeon K; Kim SH; Chung DR; Peck KR; Lee NY; Song JH
    J Clin Microbiol; 2012 Dec; 50(12):4175-7. PubMed ID: 23052301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxycycline activity against Streptococcus pneumoniae.
    Shea KW; Cunha BA; Ueno Y; Abumustafa F; Qadri SM
    Chest; 1995 Dec; 108(6):1775-6. PubMed ID: 7497817
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.